Protagonist Therapeutics, Inc. (PTGX) Stock Analysis
A live, multi-source view of Protagonist Therapeutics, Inc. (PTGX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Sector: Healthcare · Industry: Biotechnology · United States · 141 employees · protagonist-inc.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Protagonist Therapeutics, Inc. (PTGX) had a market capitalization of $9.43B, a trailing P/E of 141.5 (forward -731.7) and a beta of 1.79; the shares traded in a 52-week range of $54.50 – $160.81 (159.3% over the year).
- Market cap
- $9.43B
- Enterprise value
- $8.66B
- Trailing P/E
- 141.5
- Forward P/E
- -731.7
- Price / book
- 11.20
- EPS (trailing)
- $1.03
- EPS (forward)
- $-0.20
- Payout ratio
- 0.0%
- 52-week range
- $54.50 – $160.81
- 52-week change
- 159.3%
- Beta
- 1.79
- Average volume
- 668,847
- Shares outstanding
- 64.7M
- Short % of float
- 13.99%
- Profit margin
- 29.4%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Protagonist Therapeutics, Inc. (PTGX) last closed at $145.16 (the last completed close before that scan).
Technicals at the scan: RSI 49 (neutral territory), price -3.4% versus its 20-day average, 20-day versus 50-day average spread +5.5%, MACD histogram -1.39.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 81/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of PTGX; corporate insiders filed 0 buys and 5 sells (1 filer, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Patel Dinesh V Ph D (0B/5S). Who is trading what
RapidTradeView pick record
PTGX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Protagonist Therapeutics, Inc. (PTGX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PTGX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.